Innate Pharma
IPHA
9 hedge funds and large institutions have $158K invested in Innate Pharma in 2025 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 9 → 9 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
0.02% less ownership
Funds ownership: 0.11% → 0.09% (-0.02%)
12% less capital invested
Capital invested by funds: $179K → $158K (-$20.7K)
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$4.71K |
| 2 |
FFA
Farther Finance Advisors
San Francisco,
California
|
+$20 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$20.4K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$13.2K |
| 3 |
GI
GAMMA Investing
Foster City,
California
|
-$2.36K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$2.33K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Morgan Stanley
New York
| $103K | +$4.71K | +2,340 | +5% |
|
|
2
Citadel Advisors
Miami,
Florida
| $39.1K | -$13.2K | -6,575 | -25% |
|
|
3
UBS Group
Zurich,
Switzerland
| $9.26K | -$2.33K | -1,160 | -19% |
|
|
GI
4
GAMMA Investing
Foster City,
California
| $4.4K | -$2.36K | -1,175 | -34% |
|
5
RhumbLine Advisers
Boston,
Massachusetts
| $916 | – | – | – |
|
6
Barclays
London,
United Kingdom
| $593 | – | – | – |
|
7
Optiver Holding
Amsterdam,
Netherlands
| $197 | – | – | – |
|
|
PS
8
Principal Securities
Des Moines,
Iowa
| $87 | – | – | – |
|
|
FFA
9
Farther Finance Advisors
San Francisco,
California
| $19 | +$20 | +10 | New |
|
|
10
Millennium Management
New York
| – | -$20.4K | -11,661 | Closed |
|
IPHA Hedge Fund Activity: Q3 2025 in Review
9 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Innate Pharma (IPHA) for Q3 2025, worth a combined $158K — down 12% from $179K a quarter earlier.
Fund positioning in IPHA was balanced in Q3 2025: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 3 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $4.71K. The largest seller was Millennium Management, exiting entirely with an estimated $20.4K sold.
- 9 institutional investors held Innate Pharma (IPHA) as of Q3 2025, unchanged from Q2 2025.
- Funds reported $158K of Innate Pharma stock for Q3 2025, down 12% quarter-over-quarter.
- 1 fund opened new Innate Pharma positions in Q3 2025 and 1 closed out, a net change of 0 holders.
- The largest Innate Pharma buyer in Q3 2025 was Morgan Stanley, an estimated $4.71K added.
- The largest Innate Pharma seller in Q3 2025 was Millennium Management, an estimated $20.4K sold.
Based on aggregated 13F filings for Q3 2025.